Response Biomedical Corp.
|
(Name of Issuer)
|
|
Common Shares, without par value
|
(Title of Class of Securities)
|
|
76123L303
|
(CUSIP Number)
|
|
OrbiMed Advisors LLC
OrbiMed Advisors Limited
OrbiMed Asia GP, L.P.
OrbiMed Capital GP III LLC
Samuel D. Isaly
601 Lexington Avenue, 54th Floor
New York, NY 10022
Telephone: (212) 739-6400
Attn: Alexander M. Cooper
|
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
|
|
November 29, 2016
|
(Date of Event which Requires Filing of this Statement)
|
* |
The remainder of this cover page shall be filled out for a Reporting Person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
|
|
|
|
|
|
1
|
Names of Reporting Persons.
OrbiMed Advisors LLC
|
|||
2
|
Check the Appropriate Box if a Member of a Group (See Instructions).
(a) ☐
(b) ☐
|
|
||
3
|
SEC Use Only
|
|||
4
|
Source of Funds (See Instructions)
N/A
|
|||
5
|
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
|
☐
|
||
6
|
Citizenship or Place of Organization
Delaware
|
|||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
Sole Voting Power
0
|
||
8
|
Shared Voting Power
0 (See Item 5)
|
|||
9
|
Sole Dispositive Power
0
|
|||
10
|
Shared Dispositive Power
0 (See Item 5)
|
|||
11
|
Aggregate Amount Beneficially Owned by Each Reporting Person
0 (See Item 5)
|
|||
12
|
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
|
☐
See Item 5
|
||
13
|
Percent of Class Represented by Amount in Row (11)
0.00% (See Item 5)
|
|||
14
|
Type of Reporting Person (See Instructions)
IA
|
|
|
|
|
|
1
|
Names of Reporting Persons.
OrbiMed Advisors Limited
|
|||
2
|
Check the Appropriate Box if a Member of a Group (See Instructions).
(a) ☐
(b) ☐
|
|
||
3
|
SEC Use Only
|
|||
4
|
Source of Funds (See Instructions)
N/A
|
|||
5
|
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
|
☐
|
||
6
|
Citizenship or Place of Organization
Cayman Islands
|
|||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
Sole Voting Power
0
|
||
8
|
Shared Voting Power
0 (See Item 5)
|
|||
9
|
Sole Dispositive Power
0
|
|||
10
|
Shared Dispositive Power
0 (See Item 5)
|
|||
11
|
Aggregate Amount Beneficially Owned by Each Reporting Person
0 (See Item 5)
|
|||
12
|
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
|
☐
See Item 5
|
||
13
|
Percent of Class Represented by Amount in Row (11)
0.00% (See Item 5)
|
|||
14
|
Type of Reporting Person (See Instructions)
OO
|
|
|
|
|
|
1
|
Names of Reporting Persons.
OrbiMed Asia GP, L.P.
|
|||
2
|
Check the Appropriate Box if a Member of a Group (See Instructions).
(a) ☐
(b) ☐
|
|
||
3
|
SEC Use Only
|
|||
4
|
Source of Funds (See Instructions)
N/A
|
|||
5
|
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
|
☐
|
||
6
|
Citizenship or Place of Organization
Cayman Islands
|
|||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
Sole Voting Power
0
|
||
8
|
Shared Voting Power
0 (See Item 5)
|
|||
9
|
Sole Dispositive Power
0
|
|||
10
|
Shared Dispositive Power
0 (See Item 5)
|
|||
11
|
Aggregate Amount Beneficially Owned by Each Reporting Person
0 (See Item 5)
|
|||
12
|
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
|
☐
See Item 5
|
||
13
|
Percent of Class Represented by Amount in Row (11)
0.00% (See Item 5)
|
|||
14
|
Type of Reporting Person (See Instructions)
OO
|
|
|
|
|
|
1
|
Names of Reporting Persons.
OrbiMed Capital GP III LLC
|
|||
2
|
Check the Appropriate Box if a Member of a Group (See Instructions).
(a) ☐
(b) ☐
|
|
||
3
|
SEC Use Only
|
|||
4
|
Source of Funds (See Instructions)
N/A
|
|||
5
|
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
|
☐
|
||
6
|
Citizenship or Place of Organization
Delaware
|
|||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
Sole Voting Power
0
|
||
8
|
Shared Voting Power
0 (See Item 5)
|
|||
9
|
Sole Dispositive Power
0
|
|||
10
|
Shared Dispositive Power
0 (See Item 5)
|
|||
11
|
Aggregate Amount Beneficially Owned by Each Reporting Person
0 (See Item 5)
|
|||
12
|
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
|
☐
See Item 5
|
||
13
|
Percent of Class Represented by Amount in Row (11)
0.00% (See Item 5)
|
|||
14
|
Type of Reporting Person (See Instructions)
OO
|
|
|
|
|
|
1
|
Names of Reporting Persons.
Samuel D. Isaly
|
|||
2
|
Check the Appropriate Box if a Member of a Group (See Instructions).
(a) ☐
(b) ☐
|
|
||
3
|
SEC Use Only
|
|||
4
|
Source of Funds (See Instructions)
N/A
|
|||
5
|
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
|
☐
|
||
6
|
Citizenship or Place of Organization
United States
|
|||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
Sole Voting Power
0
|
||
8
|
Shared Voting Power
0 (See Item 5)
|
|||
9
|
Sole Dispositive Power
0
|
|||
10
|
Shared Dispositive Power
0 (See Item 5)
|
|||
11
|
Aggregate Amount Beneficially Owned by Each Reporting Person
0 (See Item 5)
|
|||
12
|
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
|
☐
See Item 5
|
||
13
|
Percent of Class Represented by Amount in Row (11)
0.00% (See Item 5)
|
|||
14
|
Type of Reporting Person (See Instructions)
IN
|
Exhibit
|
|
Title
|
N
|
|
Joint Filing Agreement, dated as of December 1, 2016, by and among OrbiMed Advisors LLC, OrbiMed Advisors Limited, OrbiMed Asia GP, L.P., OrbiMed Capital GP III LLC and Samuel D. Isaly.
|
O
|
Arrangement Agreement, dated as of June 16 2016, by and among Response Biomedical Corporation and 1077801 B.C. Ltd., a company owned by OrbiMed Asia Partners, L.P., OrbiMed Private Investments III, LP and OrbiMed Associates III, LP and Shanghai Runda Medical Technology Co., Ltd. (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Response Biomedical Corporation on June 20, 2016).
|
|
T
|
Rollover Agreement, dated as of June 16, 2016, by and among OrbiMed Private Investments III, L.P. and 1077801 B.C. Ltd. ( incorporated by reference to Exhibit T to Amendment No. 8 to Schedule 13D filed by the Reporting Persons on June 20, 2016)
|
|
U
|
Rollover Agreement, dated as of June 16, 2016, by and among OrbiMed Asia Partners, L.P. and 1077801 B.C. Ltd. (incorporated by reference to Exhibit U to Amendment No. 8 to Schedule 13D filed by the Reporting Persons on June 20, 2016).
|
|
V
|
Rollover Agreement, dated as of June 16, 2016, by and among OrbiMed Associates III, L.P. and 1077801 B.C. Ltd. (incorporated by reference to Exhibit V to Amendment No. 8 to Schedule 13D filed by the Reporting Persons on June 20, 2016).
|
Dated: December 1, 2016
|
ORBIMED ADVISORS LLC
|
|
|
|
|
||
|
|
|
|
|
By:
|
/s/ Samuel D. Isaly |
|
|
|
Samuel D. Isaly
|
|
|
|
Managing Member
|
|
|
|
|
|
|
ORBIMED ADVISORS LIMITED
|
|
|
|
|
||
|
|
|
|
|
By:
|
/s/ Samuel D. Isaly |
|
|
|
Samuel D. Isaly
|
|
|
|
Director
|
|
|
|
|
|
|
ORBIMED ASIA GP, L.P.
|
|
|
|
|
||
|
|
|
|
|
By:
|
ORBIMED ADVISORS LIMITED,
its general partner
|
|
|
|
|
|
|
By:
|
/s/ Samuel D. Isaly |
|
|
|
Samuel D. Isaly
|
|
|
|
Director
|
|
|
|
|
|
|
ORBIMED CAPITAL GP III LLC
|
|
|
|
|
||
|
|
|
|
|
By:
|
ORBIMED ADVISORS LLC,
its managing member
|
|
|
|
|
|
|
By:
|
/s/ Samuel D. Isaly |
|
|
|
Samuel D. Isaly
|
|
|
|
Managing Member
|
|
|
|
|
|
|
SAMUEL D. ISALY
|
|
|
|
|
|
|
|
By:
|
/s/ Samuel D. Isaly |
|
|
|
Samuel D. Isaly
|
|
Name
|
Position with Reporting Person
|
Principal Occupation
|
|
|
|
Samuel D. Isaly
|
Managing Member
|
Managing Member
OrbiMed Advisors LLC
|
|
|
|
Carl L. Gordon
|
Member
|
Member
OrbiMed Advisor, LLC
|
|
|
|
Sven H. Borho
German and Swedish Citizen
|
Member
|
Member
OrbiMed Advisors LLC
|
|
|
|
Jonathan T. Silverstein
|
Member
|
Member
OrbiMed Advisors LLC
|
|
|
|
W. Carter Neild
|
Member
|
Member
OrbiMed Advisors LLC
|
|
|
|
Geoffrey C. Hsu
|
Member
|
Member
OrbiMed Advisors LLC
|
|
|
|
Evan D. Sotiriou
|
Chief Financial Officer
|
Chief Financial Officer
OrbiMed Advisors LLC
|
Name
|
Position with Reporting Person
|
Principal Occupation
|
|
|
|
Samuel D. Isaly
|
Director
|
Director
OrbiMed Advisors Limited
|
|
|
|
Carl L. Gordon
|
Director
|
Director
OrbiMed Advisors Limited
|
|
|
|
Sven H. Borho
German and Swedish Citizen
|
Director
|
Director
OrbiMed Advisors Limited
|
|
|
|
Jonathan T. Silverstein
|
Director
|
Director
OrbiMed Advisors Limited
|
|
|
|
W. Carter Neild
|
Director
|
Director
OrbiMed Advisors Limited
|
|
|
|
Geoffrey C. Hsu
|
Director
|
Director
OrbiMed Advisors Limited
|
|
|
|
Jonathan J. Wang
|
Director
|
Director
OrbiMed Advisors Limited
|
|
|
|
Sunny Sharma
|
Director
|
Director
OrbiMed Advisors Limited
|
|
|
|
David G. Wang
|
Director
|
Director
OrbiMed Advisors Limited
|
|
|
|
Alexander M. Cooper
|
Director
|
Director
OrbiMed Advisors Limited
|
Dated: December 1, 2016
|
ORBIMED ADVISORS LLC
|
|
|
|
|
||
|
|
|
|
|
By:
|
/s/ Samuel D. Isaly |
|
|
|
Samuel D. Isaly
|
|
|
|
Managing Member
|
|
|
|
|
|
|
ORBIMED ADVISORS LIMITED
|
|
|
|
|
||
|
|
|
|
|
By:
|
/s/ Samuel D. Isaly |
|
|
|
Samuel D. Isaly
|
|
|
|
Director
|
|
|
|
|
|
|
ORBIMED ASIA GP, L.P.
|
|
|
|
|
||
|
|
|
|
|
By:
|
ORBIMED ADVISORS LIMITED,
its general partner
|
|
|
|
|
|
|
By:
|
/s/ Samuel D. Isaly |
|
|
|
Samuel D. Isaly
|
|
|
|
Director
|
|
|
|
|
|
|
ORBIMED CAPITAL GP III LLC
|
|
|
|
|
||
|
|
|
|
|
By:
|
ORBIMED ADVISORS LLC,
its managing member
|
|
|
|
|
|
|
By:
|
/s/ Samuel D. Isaly |
|
|
|
Samuel D. Isaly
|
|
|
|
Managing Member
|
|
|
|
|
|
|
SAMUEL D. ISALY
|
|
|
|
|
|
|
|
By:
|
/s/ Samuel D. Isaly |
|
|
|
Samuel D. Isaly
|
|